MAY 12, 2016 12:43 PM PDT

"Hide and Seek" Between Cancer and Immune Cells

WRITTEN BY: Kara Marker
Cancer cells are mutated cells that grow abnormally. Cytotoxic T cells of the immune system are designed and developed to recognize the abnormal parts and target these cells for destruction. Cancer cells are capable of evolving mechanisms for “hiding” from the immune system, though, and current immunotherapies used in conjunction with chemotherapy are designed to help boost the efficiency and success of the immune system to “seek” out cancer cells.

More than 12 million people per year are diagnosed with cancer, and a new study from the Texas A&M Health Science Center provides doctors a leg-up on cancer cells during this game of hide-and-seek by discovering a specific mechanism cancer cells incorporate to stay hidden.
 

Cancer cells that are equipped to remain hidden from the immune system often block the activity of a gene called NLRC5. This gene is responsible for regulating major histocompatibility complex (MHC) class I genes that cytotoxic T cells rely on for recognizing cancer cells. Prompted by NLRC5 regulation, MHC class I genes create molecules that sit on the surface of cancer-ridden cells waving a microscopic red flag to get the attention of circulating T cells.

Without NLRC5, T cells passing by a population of cancer cells would be completely unaware of that they were dangerous, abnormally growing cells. Disrupting the natural “anti-tumor” system is extremely dangerous, as tumors can then grow and metastasize uninhibited, and a person with this growing tumor might not be aware of their cancer until a very late stage.

In a study of 7747 biopsy samples from cancer patients enrolled in The Cancer Genome Atlas (TCGA) database, Texas A&M researchers pinpointed the precise relationship between NLRC5 expression and cancer patient survival. The longest survivors had the highest expression of NLRC5, and vice-versa.  

"We found that function and expression of NLRC5 is reduced in cancer cells by various mechanisms, and the result is immune evasion by cancer cells,” said first author Sayuri Yoshihama, MD, PhD.

NLRC5 was especially indicative of cancer patient outcomes in cases of melanoma, rectal cancer, bladder cancer, cervical cancer, and head/neck cancer. Melanoma in particular showed a 36 percent 5-year survival rate in low NLRC5 expression groups and 71 percent survival in high expression groups. Similarly, bladder cancer patients’ survival was closely related to NLRC5 levels, showing 34 percent survival with low expression of the gene and 62 percent with high expression.

The correlation between NLRC5 and cancer patient outcomes is promising to scientists and doctors who are pursuing more accurate prognoses and, eventually, better treatment options.

"No other mechanism [of cancer evading the immune system] is as dramatic as we found,” said Koichi Kobayashi, MD, PhD, lead author of the study.  

This study was recently published in Proceedings of the National Academy of Sciences.
 

Source: Texas A&M University
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 14, 2019
Immunology
OCT 14, 2019
This is How Your Immune System Responds to Ebola Vaccination
Vaccines to prevent Ebola are still in their infancy, with experimental-only versions being used only in the most dire of instances. In a new study, scient...
OCT 19, 2019
Neuroscience
OCT 19, 2019
Autism May be Linked to an Immune Disorder
Until now, diagnosis for autism spectrum disorder have relied on behavioral assessments looking for symptoms including poor social and communication skills...
OCT 23, 2019
Immunology
OCT 23, 2019
Treating Celiac Disease May Be Possible
Delivering gluten to the body in a friendly, harmless package may be the way for people with celiac disease to finally have a sandwich again. A new clinica...
JAN 22, 2020
Cancer
JAN 22, 2020
How the VISTA molecule affects immune responses
A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” resear...
FEB 04, 2020
Immunology
FEB 04, 2020
The Gut Deploys Protective Mechanisms in Coordination with Your Mealtime Habits
At mealtime, every mouthful of food contains a possible risk of incoming pathogens to the digestive system. The gut takes protective measures to account fo...
FEB 10, 2020
Immunology
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
Loading Comments...